Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 8-K, Date: 2010-05-12
Original SEC Filing: Click here

---

Webplus: SKBI/20100512/8-K_1/2_EX-99.1/000.htm SEC Original: v184608_ex99-1.htm
SKYSTAR COMMENCES TESTING ON TWO ADDITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THE COMPANY’S PRODUCT LINES The new dosage forms projected to generate $5 million in additional revenue by fiscal 2011 XI’AN, CHINA – May 12, 2010 – Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) (“Skystar” or the “Company”), The product testing process will ensure that the new dosage forms will adhere

---

---

Webplus: SKBI/20100512/8-K_1/1/000.htm SEC Original: v184608_8k.htm
FORM 8-K CURRENT REPORT Date of report (Date of earliest event reported): May 12, 2010 SKYSTAR BIO-PHARMACEUTICAL COMPANY Nevada 001-34394 33-0901534 (State or other jurisdiction of incorporation or organization) (Commission File No.) (IRS Employer Identification No.) Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xi’an, Shaanxi Province, P.R. China (8629) 8819-3188 (Issuer Telephone Number) N/A (Former name or

---

Company Information:

Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 8-K, Date: 2010-05-12CIK: 0001076939, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
RM 10601, JIEZUO PLAZA, NO. 4, FENGHUI ROAD SOUTH, GAOXIN DISTRICT
XIAN PROVINCE